Central nervous system toxicity and cerebrospinal fluid pharmacokinetics of intraventricularly administered bleomycin in beagles
Related Experiment Videos
Abstract:
The neurotoxic effects and cerebrospinal fluid (CSF) pharmacokinetics of bleomycin were evaluated in beagles after chronic intraventricular administration twice a week for 8 consecutive weeks. Bleomycin was reasonably well tolerated at doses of 0.067 to 0.3 mg/week. Doses higher than 0.3 mg/week produced marked elevation of CSF protein levels and a necrotizing vasculitis within the central nervous system. Pharmacokinetic studies were performed approximately 1 month after the completion of the toxicity studies. [3H]inulin was used as a reference compound. Both [3H]inulin and bleomycin were cleared from the CSF more slowly than in previous studies and more slowly than in normal dogs, which suggests that bulk CSF absorption was reduced by the drug, probably secondary to protein-induced blockage of the arachnoid granulations through which CSF is normally absorbed. Because a "minimally toxic" dose of bleomycin (approximately 0.1 mg/week) produces a CSF C X t of only 1.9 mg/min/ml, we believe that a Phase I clinical trial would be too dangerous given the limited therapeutic potential that a dose of 0.1 mg/week could achieve.
Insights
Bleomycin caused neurotoxicity and reduced cerebrospinal fluid (CSF) absorption in beagles at higher doses. Minimally toxic doses offer limited therapeutic potential, making Phase I clinical trials unsafe.
Area of Science:
- Neuroscience
- Pharmacology
- Toxicology
Background:
- Bleomycin is an antineoplastic agent.
- Intraventricular administration is a potential route for CNS drug delivery.
- Understanding bleomycin's neurotoxicity and pharmacokinetics is crucial for evaluating its clinical use.
Purpose of the Study:
- To evaluate the neurotoxic effects of chronic intraventricular bleomycin in beagles.
- To determine the cerebrospinal fluid (CSF) pharmacokinetics of bleomycin.
- To assess the safety and therapeutic potential for clinical trials.
Main Methods:
- Chronic intraventricular administration of bleomycin in beagles for 8 weeks.
- Dose-ranging toxicity evaluation.
- CSF pharmacokinetics using [3H]inulin as a reference compound.
Main Results:
- Bleomycin was tolerated at doses up to 0.3 mg/week.
- Higher doses ( > 0.3 mg/week) caused elevated CSF protein and CNS necrotizing vasculitis.
- CSF clearance of bleomycin and [3H]inulin was reduced, suggesting impaired CSF absorption.
Conclusions:
- Chronic intraventricular bleomycin induces neurotoxicity and impairs CSF absorption in a dose-dependent manner.
- The minimally toxic dose shows limited therapeutic potential.
- Phase I clinical trials are deemed too dangerous due to safety concerns and limited efficacy.